U.S. markets closed
  • S&P 500

    3,851.85
    +52.94 (+1.39%)
     
  • Dow 30

    31,188.38
    +257.86 (+0.83%)
     
  • Nasdaq

    13,457.25
    +260.07 (+1.97%)
     
  • Russell 2000

    2,160.62
    +9.48 (+0.44%)
     
  • Crude Oil

    53.28
    +0.30 (+0.57%)
     
  • Gold

    1,868.80
    +28.60 (+1.55%)
     
  • Silver

    25.91
    +0.59 (+2.31%)
     
  • EUR/USD

    1.2109
    -0.0024 (-0.19%)
     
  • 10-Yr Bond

    1.0900
    -0.0020 (-0.18%)
     
  • GBP/USD

    1.3659
    +0.0025 (+0.18%)
     
  • USD/JPY

    103.5300
    -0.3620 (-0.35%)
     
  • BTC-USD

    34,736.56
    +336.59 (+0.98%)
     
  • CMC Crypto 200

    688.24
    -12.37 (-1.77%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2020 Financial Results on February 23, 2021

Inspire Medical Systems, Inc.
·1 min read

MINNEAPOLIS, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, February 23. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Tuesday, February 23rd @ 5:00 p.m. Eastern Time:

Domestic:

877-407-0792

International:

201-689-8263

Conference ID:

13715465

Webcast:

http://public.viavid.com/index.php?id=143162

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989